JP2022513001A5 - - Google Patents
Info
- Publication number
- JP2022513001A5 JP2022513001A5 JP2021525603A JP2021525603A JP2022513001A5 JP 2022513001 A5 JP2022513001 A5 JP 2022513001A5 JP 2021525603 A JP2021525603 A JP 2021525603A JP 2021525603 A JP2021525603 A JP 2021525603A JP 2022513001 A5 JP2022513001 A5 JP 2022513001A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- immunogenic composition
- concentration
- present
- hbsag antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024157339A JP2024174990A (ja) | 2018-11-13 | 2024-09-11 | Ｂ型肝炎の治療のための免疫原性組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862760439P | 2018-11-13 | 2018-11-13 | |
| US62/760,439 | 2018-11-13 | ||
| PCT/IB2019/001230 WO2020099927A1 (en) | 2018-11-13 | 2019-11-13 | Immunogenic compositions for treatment of hepatitis b |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024157339A Division JP2024174990A (ja) | 2018-11-13 | 2024-09-11 | Ｂ型肝炎の治療のための免疫原性組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022513001A JP2022513001A (ja) | 2022-02-07 |
| JP2022513001A5 true JP2022513001A5 (https=) | 2022-10-28 |
Family
ID=70731781
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021525603A Pending JP2022513001A (ja) | 2018-11-13 | 2019-11-13 | Ｂ型肝炎の治療のための免疫原性組成物 |
| JP2024157339A Pending JP2024174990A (ja) | 2018-11-13 | 2024-09-11 | Ｂ型肝炎の治療のための免疫原性組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024157339A Pending JP2024174990A (ja) | 2018-11-13 | 2024-09-11 | Ｂ型肝炎の治療のための免疫原性組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12128100B2 (https=) |
| EP (1) | EP3880244A4 (https=) |
| JP (2) | JP2022513001A (https=) |
| KR (1) | KR102943479B1 (https=) |
| CN (2) | CN118987191A (https=) |
| BR (1) | BR112021009234A2 (https=) |
| IL (2) | IL314712A (https=) |
| MX (1) | MX2021005588A (https=) |
| WO (1) | WO2020099927A1 (https=) |
| ZA (1) | ZA202103976B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020099927A1 (en) | 2018-11-13 | 2020-05-22 | Variation Biotechnologies Inc. | Immunogenic compositions for treatment of hepatitis b |
| US20240123060A1 (en) * | 2019-06-21 | 2024-04-18 | Variation Biotechnologies Inc. | Improved therapeutic composition comprising hepatitis b antigen having s, pre-s1 and pre-s2 protein, aluminium phosphate and interferon-alpha and use thereof for treatment of hepatitis b |
| AU2024313135A1 (en) | 2023-06-23 | 2026-01-22 | Brii Biosciences, Inc. | Assessment and treatment of chronic hepatitis b |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5242812A (en) | 1989-02-07 | 1993-09-07 | Bio-Technology General Corp. | Method for production and purification of hepatitis B vaccine |
| MA22842A1 (fr) | 1992-03-27 | 1993-10-01 | Smithkline Beecham Biolog | Procede de preparation de compositions de vaccin. |
| GB9503863D0 (en) | 1995-02-25 | 1995-04-19 | Smithkline Beecham Biolog | Vaccine compositions |
| GB9809507D0 (en) * | 1998-05-01 | 1998-07-01 | Smithkline Beecham Biolog | Novel composition |
| CN1305527C (zh) | 2003-11-21 | 2007-03-21 | 薛平 | 乙型肝炎治疗疫苗及其制备方法 |
| KR100836745B1 (ko) | 2007-01-31 | 2008-06-10 | (주)두비엘 | Ｈｂｖ 백신 및 그의 제조 방법 |
| CN102949717A (zh) | 2012-07-06 | 2013-03-06 | 中国疾病预防控制中心病毒病预防控制所 | 一种含poly I:C佐剂的新型乙肝疫苗制剂 |
| CN104043120B (zh) | 2013-03-13 | 2017-05-31 | 南京赛威信生物医药有限公司 | 乙型肝炎疫苗 |
| WO2018166298A1 (en) | 2017-03-13 | 2018-09-20 | Fudan University | Immunopotentiator, immunotherapeutic pharmaceutical composition and its preparation and use |
| WO2020099927A1 (en) * | 2018-11-13 | 2020-05-22 | Variation Biotechnologies Inc. | Immunogenic compositions for treatment of hepatitis b |
| US20240123060A1 (en) | 2019-06-21 | 2024-04-18 | Variation Biotechnologies Inc. | Improved therapeutic composition comprising hepatitis b antigen having s, pre-s1 and pre-s2 protein, aluminium phosphate and interferon-alpha and use thereof for treatment of hepatitis b |
-
2019
- 2019-11-13 WO PCT/IB2019/001230 patent/WO2020099927A1/en not_active Ceased
- 2019-11-13 BR BR112021009234-0A patent/BR112021009234A2/pt unknown
- 2019-11-13 IL IL314712A patent/IL314712A/en unknown
- 2019-11-13 EP EP19885196.6A patent/EP3880244A4/en active Pending
- 2019-11-13 KR KR1020217018153A patent/KR102943479B1/ko active Active
- 2019-11-13 CN CN202410981157.0A patent/CN118987191A/zh active Pending
- 2019-11-13 IL IL283039A patent/IL283039B2/en unknown
- 2019-11-13 JP JP2021525603A patent/JP2022513001A/ja active Pending
- 2019-11-13 CN CN201980074891.6A patent/CN113423423B/zh active Active
- 2019-11-13 MX MX2021005588A patent/MX2021005588A/es unknown
- 2019-11-13 US US17/293,431 patent/US12128100B2/en active Active
-
2021
- 2021-06-09 ZA ZA2021/03976A patent/ZA202103976B/en unknown
-
2024
- 2024-09-11 JP JP2024157339A patent/JP2024174990A/ja active Pending
- 2024-09-12 US US18/883,612 patent/US20250269013A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tajiri et al. | Unsolved problems and future perspectives of hepatitis B virus vaccination | |
| Yoo et al. | Twenty‐four‐week clevudine therapy showed potent and sustained antiviral activity in HBeAg‐positive chronic hepatitis B | |
| Hou et al. | Epidemiology and prevention of hepatitis B virus infection | |
| Lin et al. | the prevention of hepatitis B‐related hepatocellular carcinoma | |
| Churin et al. | Hepatitis B virus large surface protein: function and fame | |
| JP2016128513A5 (https=) | ||
| JP2022513001A5 (https=) | ||
| JP2017524682A5 (https=) | ||
| CN104487090B (zh) | 一种用于预防或治疗突变型乙型肝炎病毒感染的抗体组合物 | |
| Xu et al. | Hepatitis B virus-related hepatocellular carcinoma: Pathogenic mechanisms and novel therapeutic interventions | |
| JP2017515508A5 (https=) | ||
| Fernández et al. | Five-year follow-up of chronic hepatitis B patients immunized by nasal route with the therapeutic vaccine HeberNasvac | |
| JP2019510064A5 (https=) | ||
| TW201735945A (zh) | 包括b型肝炎病毒之表面及核殼體抗原的藥學組成物 | |
| JP2007504112A5 (https=) | ||
| Xue et al. | An autophagosome-based therapeutic vaccine for HBV infection: a preclinical evaluation | |
| Tsai et al. | Immunopathology of hepatitis B virus infection | |
| JP2024105291A (ja) | Ｂ型肝炎感染症を処置するための方法および組成物 | |
| CN102665687A (zh) | 用于细胞刺激随后进行治疗性免疫的乙肝病毒抗原制剂 | |
| Boortalary et al. | Achieving a cure: the next frontier in hepatitis B treatment | |
| Huang et al. | New advances in hepatitis B vaccination for adults | |
| JP2022513438A5 (https=) | ||
| Pan et al. | New anti-hepatitis B virus drugs under development and evaluation | |
| JP2020509035A5 (https=) | ||
| Trujillo et al. | Optimization of a therapeutic vaccine candidate by studying routes, immunization schedules and antigen doses in HBsAg-positive transgenic mice |